What Happened?
Shares of lab services company Charles River Laboratories (NYSE: CRL) jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.
Is now the time to buy Charles River Laboratories? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Charles River Laboratories’s shares are somewhat volatile and have had 13 moves greater than 5% over the last year. But moves this big are rare even for Charles River Laboratories and indicate this news significantly impacted the market’s perception of the business.
Charles River Laboratories is down 25.5% since the beginning of the year, and at $136.06 per share, it is trading 44.5% below its 52-week high of $245.29 from July 2024. Investors who bought $1,000 worth of Charles River Laboratories’s shares 5 years ago would now be looking at an investment worth $869.06.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
